Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | -- | 8.00K | 500.00K | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | -- | 8.00K | 500.00K | 1.00M |
| Cost of Revenue | 263.00K | 4.81M | 7.22M | 6.34M | 6.85M |
| Gross Profit | 737.00K | -4.81M | -7.21M | -5.84M | -5.85M |
| SG&A Expenses | 1.51M | 2.26M | 1.44M | 1.50M | 1.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.77M | 7.07M | 8.65M | 7.84M | 8.17M |
| Operating Income | -774.00K | -7.07M | -8.65M | -7.34M | -7.17M |
| Income Before Tax | -763.00K | -7.35M | -8.07M | -6.20M | -7.21M |
| Income Tax Expenses | -- | -- | -- | 2.00K | -- |
| Earnings from Continuing Operations | -763.00K | -7.35M | -8.07M | -6.20M | -7.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -763.00K | -7.35M | -8.07M | -6.20M | -7.21M |
| EBIT | -774.00K | -7.07M | -8.65M | -7.34M | -7.17M |
| EBITDA | -772.00K | -7.07M | -8.64M | -7.34M | -7.16M |
| EPS Basic | -0.02 | -0.24 | -0.26 | -0.20 | -0.23 |
| Normalized Basic EPS | -0.02 | -0.15 | -0.16 | -0.13 | -0.15 |
| EPS Diluted | -0.02 | -0.24 | -0.26 | -0.20 | -0.23 |
| Normalized Diluted EPS | -0.02 | -0.15 | -0.16 | -0.13 | -0.15 |
| Average Basic Shares Outstanding | 30.90M | 30.84M | 30.83M | 30.83M | 30.83M |
| Average Diluted Shares Outstanding | 30.90M | 30.84M | 30.83M | 30.83M | 30.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |